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Abstract  
 
Background: Cu/Zn superoxide dismutase (SOD1) reduction prolongs survival in 
SOD1-transgenic animal models. Pyrimethamine produces dose dependent SOD1 
reduction in cell culture systems. A previous phase-1 trial showed pyrimethamine lowers 
SOD1 levels in leucocytes in patients with SOD1 mutations. This study investigated 
whether pyrimethamine lowered SOD1 levels in the cerebrospinal fluid (CSF) in patients 
carrying SOD1 mutations linked to ALS (fALS/SOD1). 
 
Methods and Study Design: Multicenter (5 sites), open-label, 9-month duration, dose-
ranging, to determine safety and efficacy of pyrimethamine to lower SOD1 levels in the 
CSF of FALS/SOD1. All participants underwent 3 lumbar punctures, blood draw, clinical 
assessment of strength, motor function, quality of life, and adverse effects assessments. 
SOD1 levels were measured in erythrocytes and CSF. Pyrimethamine was measured in 
plasma and CSF. Appel ALS, ALSFRS-R and single item McGill Quality of Life (SIS-
MQoL) were measured at screening, visit 6 and 9. 
 
Results: We enrolled 32 patients; 24 completed 6 visits (18 weeks) and 21 completed all 
study visits. A linear mixed effects model showed a significant reduction in CSF SOD1 at 
visit 6 (p<0.001) with a mean reduction of 13.5% (95% CI: 8.4, 18.5) and at visit 9 
(p<0.001) with a mean reduction of 10.5% (95% CI: 5.2, 15.8).  
 
Interpretation: Pyrimethamine is safe and well tolerated in ALS. Pyrimethamine is 
capable of producing a significant reduction in total CSF SOD1 protein content in 
patients with ALS caused by different SOD1 mutations. Further long-term studies are 
warranted to assess clinical efficacy. 
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Introduction 
 
Amyotrophic Lateral Sclerosis (ALS) is a relentlessly progressive neurodegenerative 
disease of upper and lower motor neurons causing progressive weakness of limbs, 
swallowing and breathing resulting in death within 3-5 years (1). The cause is uncertain 
in most patients but in approximately 10% of patients, the disease is familial (2). Since 
1993, mutations in over 36 genes have been associated with causing ALS(3). Mutations 
in the cytoplasmic free radical scavenging enzyme Cu/Zn superoxide dismutase (SOD1) 
accounts for 3-23% of familial cases (fALS) and 1-3% of sporadic cases (2-4). 
Transgenic mice overexpressing mutant human SOD1 develop a progressive motor 
neuron degenerative disease mimicking human ALS, while knock out of the murine 
SOD1 gene does not result in a similar phenotype (5). These findings combined with the 
observation that there is no relationship between the level of SOD1 activity and patient 
prognosis suggest that there is a toxic gain of function for the SOD1 mutant molecule 
with a predilection for the motor system (3). Reducing the content of mutant SOD1 
(mSOD1) attenuates disease progression proportionate to the suppression of mutant 
protein using interfering RNA (RNAi) (6). Collective evidence supports the hypothesis 
that lowering the total SOD1 protein content may be beneficial and influence the disease 
course in ALS. Attempts to lower SOD1 expression are currently being pursued using 
anti sense oligonucleotides (ASO) (7) and by increasing consumption of SOD1 by 
activating heat shock proteins (8) via the drug arimoclomol. Using FDA approved drugs 
that also have the ability to lower SOD1 content is another approach (9). Monitoring the 
CSF SOD1 protein level has been identified as a reliable biomarker for SOD1 reduction 
within the anterior horn cell in transgenic rats with SOD1 mediated ALS(7). In humans 
with ALS and SOD1 mutations, CSF SOD1 shows minimal variability and is a reliable 
biomarker for SOD1 mediated fALS (10). We have previously reported that oral 
treatment with pyrimethamine in ALS patients with a mutation in SOD1 resulted in a 
reduction of SOD1 levels in peripheral blood leucocytes and, in both patients studied, a 
reduction in SOD1 protein content and activity in the cerebrospinal fluid (CSF)(9). We 
now report a phase I/II study whose primary aim was to determine if pyrimethamine 
lowers SOD1 in the CSF in ALS patients with a wide variety of SOD1 mutations and 
over a longer period of time and a secondary aim to establish safety and tolerability.  
 
Methods 
The Institutional Review Board at Weill Cornell Medicine approved this study, followed 
by approval by the relevant institutional or national Ethical Review Boards at the 
participating institutions in the USA, Italy, Germany and Sweden, following FDA and 
EMA regulations and adhering to the Principles of the Declaration of Helsinki (WMA, 
1964). The study was registered at www.clinicaltrials.gov as NCT01083667. This was a 
single arm open-label study with the primary endpoint to determine if oral medication 
with pyrimethamine results in a reduction of CSF SOD1 levels in ALS patients with 
different types of SOD1 mutations. Based on our earlier study (9) the target dose was set 
at 75 mg per day supplemented with 10 mg of leucovorin. However, different dosing was 
achieved due to reductions required to maintain tolerability. We enrolled 32 patients 
(Table 1).  
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Inclusion criteria were: the presence of objective weakness in at least one neural segment 
and a pathogenic mutation in SOD1 (El Escorial Definite ALS revised (11)); age 18 years 
or older; capable of providing written informed consent and complying with trial 
procedures; not taking riluzole or on a stable dose for 30 days or more not taking 
coenzyme Q10 or on a stable dose and brand for 30 days or more. Subjects were 
excluded if there was a history of malabsorption syndrome; exposure to any other agents 
considered a therapeutic target for ALS within 30 days of entry into this study; women 
who are pregnant or planning on becoming pregnant; women who are breastfeeding; 
alcoholism; taking phenytoin or other medications that may interfere with folate levels, 
seizures, megaloblastic anemia, folate deficiency, cardiac rhythm disorders, impaired 
renal and liver function, tracheostomy or mechanical ventilation; use of any of the 
following medications: cytosine arabinoside; methotrexate; daunorubicin; sulfonamides; 
zidovudine; lorazepam; warfarin; sulfamethoxazole; trimethoprim; and lithium. 
 
There were 10 visits: screen/baseline, weeks 3, 6, 9, 12, 15, 18, 24, 30 and 36. Visits at 
weeks 0, 18, and 36 were critical visits for data acquisition.  At all visits, weight, vital 
signs and concomitant medication screen combined with adverse effect assessment 
occurred. Blood for SOD1 and pyrimethamine levels was obtained. At weeks 0, 18 and 
36 a lumbar puncture was performed. At weeks 0, 6,18 and 36 we measured the ALS 
Functional Rating Scale, revised (ALSFRSr), Appel ALS Score (AALS), and the single 
item McGill quality of life score (MQOL-SIS). The ALSFRSr score is a questionnaire 
based assessment of motor function that has been validated in natural history studies of 
ALS and therapeutic trials (12). The AALS score is an objective measure of global motor 
function that has been validated in natural history studies and therapeutic trials (13). The 
MQOL-SIS is a single question in which the patient rates their overall quality of life on a 
scale from 1-10 (10 being the best possible and 0 being the worst possible) for the past 48 
hours. MQOL-SIS has good correlation with ALS QOL (14). 
 
Summary of Dose Escalation and Algorithm for Reduction: Pyrimethamine was supplied 
in 25 mg tablets (Core Pharma, LLC). The target dose was 75 mg based on our 
experience in the first study of pyrimethamine (9) where 100 mg was poorly tolerated but 
75 mg was deemed to be a dose that most patients could tolerate over an extended period 
of time. The escalation of dose was as follows: at baseline, patients started taking a 25 mg 
tablet daily together with 5 mg leucovorin twice daily. The leucovorin remained at the 
same dose for the duration of the study. Pyrimethamine dose increased to 37.5 mg at 3 
weeks; 50 mg 6 weeks, 62.5 mg 9 weeks and 75 mg at 12 weeks. Patients remained at 75 
mg for the duration of the study (36 weeks) if tolerated.  
 
Adverse effects were graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0. A defined algorithm existed to limit dose escalation or dose 
reduction. Escalation was stopped if any of the following symptoms achieved a grade 2 
or above level: nausea, diarrhea, vomiting, glossitis, heart rate change (>130 bpm or > 
50% over baseline on two separate measurements).  
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Reduction of dose occurred as follows: 75 mg to 50 mg; 50 to 37.5; 37.5 to 25. Reduction 
was mandated if either one grade 3 or two or more grade 2 of the adverse effects were 
identified, including: persistent nausea, persistent diarrhea, persistent vomiting, persistent 
heart rate change, and persistent anemia (> 1 study visit). Once dose reduction occurred 
or escalation was stopped, there were no further attempts to change the dose of 
medication until the end of the study.  
 
Collection of blood 
Venous blood samples were collected in vacuum tubes containing EDTA as 
anticoagulant. They were centrifuged at 1500xg for 15 min and were separated into 
plasma, buffy coat and erythrocytes. The samples were stored at -80° C until analysis.  
 
Collection of CSF 
Lumbar puncture to obtain cerebrospinal fluid (CSF) was performed in all patients at 
baseline, visit 6 (18 weeks) and visit 9 (36 weeks). The samples were stored at -80° C 
until analysis. Specimens from tube #3 were sent for SOD1 analysis.  
 
SOD1 enzymatic activity in erythrocytes 
The SOD1 enzymatic activity was analysed in erythrocytes by the direct 
spectrophotometric method using potassium superoxide as previously described (15, 16). 
The activity was related to the content of hemoglobin in the erythrocyte lysates. There is 
a strong correlation between amounts of SOD1 protein measured by ELISA and the 
SOD1 enzymatic activity (16).  
 
SOD1 protein in CSF  
For analysis of SOD1 protein, an ELISA based on rabbit and goat anti-native human 
SOD1 antibodies was used (16). The rabbit antibody was used as a primary antibody and 
the goat antibody as the secondary antibody. The ELISA was standardized with a human 
hemolysate, with the SOD1 content calibrated against pure human SOD1, the 
concentration of which was determined by quantitative amino acid analysis (17).  
 
Measurement of pyrimethamine in plasma and CSF 
A liquid chromatography/mass spectroscopy method was used for analysis of 
pyrimethamine in both plasma and CSF. Protein precipitation method was used for 
sample extraction with a sample size of 50µL (Primera Analytical Solutions Corp., 
Princeton, NJ). 
 
 
Statistical Methods 
 
Based on previous data, the mean ± SD baseline SOD1 content was estimated to be 112 ± 
30 ng/cc (9). It was determined that enrollment of 34 patients with ALS and  mutations in 
SOD1 would provide 80% power at a two-sided alpha level of 0.025 to detect a 15% 
reduction in SOD1 content from baseline at 18 weeks and/or 36 weeks post study 
commencement. A total of 40 patients were to be enrolled to account for potential drop 
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outs. However, the trial was terminated after the enrollment of 32 patients due to a 
sudden and exorbitant increase in the cost of pyrimethamine(18). 
 
Continuous variables are presented as means with standard deviations or medians with 1
st
 
and 3
rd
 quartiles. Kaplan-Meier analysis was used to estimate the median, 1
st
 quartile, and 
3
rd
 quartile duration of disease. Categorical variables are presented as counts and 
percentages. Continuous baseline variables were compared between patients with 
complete vs. incomplete followup data using two-sample t-tests or Wilcoxon rank-sum 
tests, depending upon the distribution of the data. Categorical baseline variables were 
compared between patients with complete vs. incomplete followup data using χ
2
 or 
Fisher’s exact tests, as appropriate. The change in continuous outcomes from baseline 
across repeated measurements was modeled using linear mixed effects modeling with a 
Gaussian random intercept, producing equivalent point estimates to a generalized 
estimating equations approach with a compound symmetric correlation structure. Given 
the limited sample size, each model contained timepoint as the sole predictor (treated as a 
fixed effect). A compound symmetric correlation structure was employed because the 
models would not converge with more complex correlation structures. As a sensitivity 
analysis, the mean change in continuous outcomes over time was calculated after 
multiple imputation of missing values. Specifically, age, sex, and baseline ALSFRSr, 
AALS, and MQOL-SIS scores were used to to create 10 imputed datasets. Results were 
combined to obtain pooled mixed effects model estimates of the change in continuous 
outcomes from baseline to 6, 18, and 36 weeks. All statistical hypothesis tests were two-
sided, with P < 0.05 considered statistically significant. Statistical analyses were 
performed with SAS Version 9.3 (SAS Institute, Cary, NC) and the ICE package 
implemented in STATA version 14 (Stata Corporation, College Station, TX). 
 
 
Results 
 
After signing informed consent, 32 patients were screened, 16 men and 16 women whose 
symptoms started at a mean (range) age of 47.0 years (19-67). All patients had confirmed 
mutations in SOD1, 21 were unique and 3 were novel (H80Y, V119F, E133K; Table 1). 
At baseline, the mean AALS score was 65.6 (34-115). The mean ALSFRSr score was 
40.1 (27-47). 22 patients were on a stable dose of riluzole at entry and continued 
throughout the study; 8 were riluzole free.  
 
Of the 32 patients enrolled, 8 dropped out before the scheduled 2
nd
 lumbar puncture; 6 
due to disease progression; 2 due to inability to tolerate medication. Therefore, 24 
samples were available to analyze at week 18 (Fig 1). In the final 18 weeks of the study, 
two additional patients dropped out (leaving 22 potential CSF samples for analysis). 
However, one patient declined the last LP and AALS score, leaving 21 patients with 3 
longitudinal CSF, blood and clinical assessments.  
 
The results from all measures obtained during the study, expressed as change from 
baseline, are presented in Table 2. The primary aim of the study was to determine if 
patients with ALS associated with an SOD1 mutation taking pyrimethamine showed a 
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reduction in the level of CSF SOD1. The mean reduction of CSF SOD1 in all patients at 
18 and 36 weeks was 13.5% (raw mean reduction [95% CI]: 8.8ng/ml [5.5, 12.1], 
p<0.001) and 10.5% (6.8ng/ml [3.4, 10.3], p<0.001) (Table 2). Achieving a significant 
reduction in CSF SOD1, an accepted biomarker for SOD1 associated fALS over the 9-
month study period fulfilled the primary aim of this protocol. Peripheral blood SOD1 did 
not change during the study. Pyrimethamine levels in the CSF approximated 10% that 
seen in the plasma. During the final 18 weeks of the study, the mean dose of 
pyrimethamine declined as did CSF SOD1 levels suggesting a dose response effect (Fig 
2).  
 
Of the 32 patients enrolled 24 completed 18 weeks of treatment with two lumbar 
punctures. The change in CSF SOD1 from baseline in each patient per mutation, 
undergoing two lumbar punctures 4.5 months apart (18 weeks) is shown in Figure 3. 
There is substantial variation between patients and between patients with the same 
mutation. Nine patients (39%) showed a reduction of 20% or more from baseline.  
 
Of the 22 patients completing the study (36 weeks of treatment) 13 were able to continue 
at the protocol-directed 75 mg. One patient refused the last LP leaving 12 patients with 
CSF to analyze. In 9 (75%) SOD1 reduction exceeded 14% (14.3 to 24.3%). In one, a 
woman heterozygous for A4V, the visit 9 (36 week) SOD1 level increased by more than 
20% from baseline and more than 40% from the SOD1 measurement at week 18. 
Excluding that patient, protocol compliant patients showed a mean decrease of 15.6% at 
36 weeks. 
 
CSF SOD1 normal variation is minimal. One study showed that CSF SOD1 varies by 
±7.1% on repeated analysis (10). Moreover, it appears that CSF SOD1 content does not 
decrease over time in ALS patients not treated with pyrimethamine. For comparison, we 
analyzed CSF SOD1 in 12 untreated ALS patients without SOD1 mutations that had 
lumbar punctures on 2 occasions. The SOD1content increased by an average of 2.8% 
over a mean interval of 13.8 months (from 98.3 ± 33.5 to 102.9 ± 35.7 ng/ml).  
 
There were 11 dropouts (34%). We compared baseline characteristics between patients 
who did and did not complete the study (Table 3A) and performed multiple imputation 
analyses on all measures (Table 3B). Point estimates from multiple imputation and 
available case analyses were fairly similar for most outcomes and time points. However, 
multiple imputation analysis did show a less pronounced decrease in CSF SOD1 levels 
between baseline and 36 weeks compared to complete case analysis (9.0% vs. 10.5%, 
respectively) and a greater increase in AALS score over the same time period (29 vs. 18, 
respectively). Comparing baseline features between patients that completed relative to 
those that dropped out showed those that did not complete the 36 week protocol were 
often women with greater burden of disease (admission AALS/ALSFRSr in fully 
protocol compliant 53/39 vs 76/42 in dropouts). There is no change in self perceived 
quality of life between baseline and completion. 
 
 
Does pyrimethamine slow progression of FALS? 
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Although the primary aim of the study was to determine if pyrimethamine significantly 
lowers CSF SOD1 levels, we found patients on pyrimethamine may have progressed 
slower than expected based on data from historical studies of mutant SOD1 patients and 
placebo groups from other therapeutic trials.  The mean change from baseline showed a 
significant progression using both AALS and ALSFRSr measures at 18 and 36 weeks 
(Table 2), but the rate of change was 2ppm and -0.7ppm respectively for all patients. Of 
note, disease progression in patients with A4V/A4T mutations needs to be considered 
separately because of marked differences in progression and survival (19). In one study, 
survival in patients with non-A4V mutations showed a mean disease duration to be 6.6 
+/- 7 years compared to 1.4+/-0.7 years in A4V and 0.8 +/- 0.1 months in A4T 
patients(19).   
 
Of our non-A4V patients, mean progression was 0.52 ppm on the ALSFRSr scale and 
0.92 ppm on the AALS score (Fig 4 A,B). In comparison placebo and historical controls 
from non FALS patients show average ALSFRSr/AALS change to be 1.18 +/- 0.85 and 
4.70 ppm respectively (20, 21)  
 
We had 4 patients that showed no change in ALSFRSr or AALS over the 9-month period 
(i.e. non-progressors) The mutations were H46R, I113T, L144F, A95T. All of these 
mutations are known to produce a progressive motor neuron disorder with either a 
protracted or a variable time course (22, 23).  
 
Progression is more uniform in rapidly progressive mutations, such as A4V and A4T. 
Our population included 3 patients with A4V (2; numbers 2,3 Table 1) and A4T (1; 
Number 1, Table 1) who were fully compliant with the protocol and completed the entire 
36-week treatment period with ALSFRSr, AALS scores and CSF SOD1 values (three 
other A4V patients dropped out because of disease progression). For the first 18 weeks, 
the rate of change of AALS/ALSFRSr was 2.5/1.0 ppm for the patients with A4V and 
4/2ppm for the patient with A4T; the last 4 months showed an increase to an average of 
12/4.35ppm for A4V and 6.25/1.5 ppm for A4T (Fig 5 A,B). The median [Q1, Q3] 
duration of disease for the 5 A4V patients was 20 [16, 22] months and the duration of 
disease for the A4T patient was 24 months.  
  
There was a proportionate reduction in SOD1 levels in all 3 compliant A4V/T subjects 
during the first 18 weeks of the study (mean 16.6 ng/ml). One A4V patient showed a 
reduction in SOD1 content of 20% during the first 4.5 months. However, during the last 
4.5 months of the study, SOD1 content increased 47%. This subject had the shortest 
disease duration of 19 months and a change in AALS rate of change from 4.0 ppm during 
the first half to 6.25 ppm during the last 18 weeks. She expired from disease related 
respiratory failure 2 months after completing the study. The 2
nd
 A4V patient showed a 
slower but progressive decline in SOD1 content and he lived 22 months, i.e. almost 
double the mean survival time for patients with A4V (19). The patient with A4T, often 
more aggressive that A4V lived the longest at 24 months from symptom onset. Clearly no 
conclusions can be drawn from these three A4V/T patients but these observations seem to 
suggest a slowing of progression in this most aggressive of familial diseases. 
 
Page 8 of 23
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
Lange, DJ, et al  
 
 
9 
 
 
Adverse Events 
There were 30 unique symptoms classified as adverse effects, 77 in total. Among the 
most common, headache (n=13/32 patients; most associated with lumbar puncture), 
nausea (14/32), diarrhea (6/32), pain (5/32), falls, upper respiratory tract infections, 
shortness of breath/aspiration pneumonia and fatigue (4/32), weight loss (3/32), 
decreased appetite and rash (2/32), nightmares, lightheadedness, hunger, dysgeusia 
(1/32). Seven patients had grade 3 adverse effects encompassing headache (n=3), 
aspiration pneumonia, weight loss, shortness of breath, UTI. One patient had shortness of 
breath deemed to be grade 4. There was no increase in adverse events in the patients 
taking riluzole relative to those not taking that medication. 
 
Quality of Life (MQOL) 
The mean score from the MQOL SIS showed no significant change during the duration of 
the study (Table 3). However, when individual patients with more aggressive mutations, 
such as A4V and A4T were measured, there was a decline in MQOL-SIS.  
 
Discussion 
To our knowledge, this is the first study in humans with ALS that targeted and achieved a 
significant reduction of an ALS biomarker in the CSF: the content of SOD1 (10). The 
degree of reduction varied among patients, but, on average, the reduction of 13.5% 
relative to baseline was statistically significant with the greatest reduction noted being 
46%. There was also a dose response observed with respect to mean dose of 
pyrimethamine relative to mean reduction of SOD1 CSF content.  
 
In humans, it is unknown if lowering of CSF SOD1 attenuates disease progression and if 
it does, what the critical threshold is, if any. We originally targeted 15% based on our 
observations in our first study. However, subsequent studies showed that normal 
variation in CSF does not exceed 7.1% (10). Total CSF SOD1 content includes both wild 
type and mutant proteins. Owing to widely variable stabilities, the mutant SOD1s are 
degraded in the CNS at variable rates. Depending on the mutation, the mutant SOD1 in 
the CNS have, in earlier studies, been found to vary from nearly 100% (for stable 
mutants) to around 0.5% (highly unstable truncating mutations) of the amounts of wild 
type SOD1 in heterozygous mutant SOD1 patients(24, 25). This is reflected in our highly 
variable amounts of SOD1 in CSF from our patient population, which overall are lower 
than those found in the time-course study in ALS patients without SOD1 mutations. 
Therefore, a small reduction in total SOD1 may cause a large or minimal change in 
mutant SOD1. The technology to reliably measure the relative composition of wild type 
and mutant SOD1 in the CSF is not yet available.  
 
Our findings suggest that there may be slowing of progression using historical controls. 
However, patients with fALS may have a more variable course than sporadic disease, 
sometimes unusually long. Therefore drawing any conclusion about pyrimethamine’s 
impact on disease progression from these studies would be incorrect and misleading. Our 
findings should only serve as a basis for further studies sufficiently powered to determine 
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if pyrimethamine will change rate of progression.  
 
The mechanism behind the lowering of the SOD1 content by pyrimethamine is not 
known. If the synthesis of the protein is reduced it is likely that the wild type and mutant 
SOD1s are affected to equal extents. However, our results show excellent CNS 
penetration. Pyrimethamine is one of the lipophilic anti-folates (26). More than 90% of 
pyrimethamine is (27) is bound to plasma proteins suggesting there is 10% free 
pyrimethamine in the plasma. This equals the 10% of plasma levels we found in the CSF. 
The proportion of pyrimethamine bound to protein in the CSF should be negligible given 
the very low CSF protein content. 
 
A single study found that pyrimethamine has no impact on SOD1 levels when 
administered to cell cultures or homogenates of liver, spinal cord and brain of wild type 
mice (28). Both our previous study and the present study find that there are no significant 
changes in SOD1 content in erythrocytes. However, our previous work showed a 
reduction in leucocytes and now in CSF, a very different tissue from the ones tested by 
Wright et al. (28). Perhaps of importance, different methodologies to assay SOD1 were 
used by Wright et al. and us.  
 
In our first study, pyrimethamine was poorly tolerated at higher doses, especially at the 
100 mg dose causing multiple adjustments in dose (9). We therefore set 75 mg as the 
maximum dose and established strict criteria for dose reduction after which the tolerated 
dose would not be altered. This, allowed us to discern a possible dose impact on CSF 
SOD1 levels, which we did observe. Therefore, it would be important to try to achieve 
the target of 75 mg per day. When factors that impacted dose reduction were reviewed, 
the severity of illness at entry seemed to be the best predictor of successful escalation to 
and maintenance of the maximum dose. In future studies, a maximum level of disease 
severity prior to entry should be established 
 
The McGill Quality of Life Single Item Scale (MQOL-SIS) is a validated scale found to 
be useful in patients with ALS (14, 29). Our results show that over a 9-month period, 
there is no difference in MQoL-SIS, and in fact, in some patients, there was a self-
perceived improvement in QoL. Of import, there is no significant decrease in QOL over 
the 9 month study. However, in rapidly progressive forms (A4V/A4T), weakness and 
QoL declines as observed by others (30).  
 
 
This is the largest prospective clinical and biological investigation of patients with FALS 
in the literature to date. There are, however, limitations to this study. We admitted all 
patients with varying levels of disease severity, and patients with higher disease burden 
were more likely to drop out. Our multiple imputation results suggest the possibility that 
results from the available case analysis were biased towards a greater average decrease in 
CSF SOD1 or lesser average worsening in disease than would have been observed had 
these sicker patients remained in the trial. Future power analyses should likely target 
levels exceeding 7% change in CSF content We are not certain that patients willing to 
undergo 3-4 lumbar punctures might in some way be different from those not willing to 
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have invasive procedures. We also did not study patients with sporadic ALS in whom 
misfolded wild type SOD1 may act like the mutant protein justifying use of potential 
SOD1 reducing therapies in this disease(31) (32) (33).  Despite these limitations we 
showed for the first time in humans, a pharmacologic agent caused a significant reduction 
in CSF SOD1 in patients with ALS and SOD1 mutations.  Although no comment can be 
made with confidence regarding impact on disease progression, slowing relative to 
historical controls may be present and further study regarding impact on disease 
progression and its relation to SOD1 reduction is needed.  
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Figure Legends 
 
Figure 1: Baseline values of CSF SOD1 protein content according to mutation in each 
subject with two lumbar punctures. 
 
Figure 2. Dose dependent change in CSF SOD1 content in patients with ALS at (A) visit 
6 (18 weeks) and (B) visit 9 (36 weeks)  
 
Figure 3. Percent change from baseline in CSF SOD1 content at 18 weeks of treatment 
according to mutation.   
 
Figure 4. Rate of change expressed as points per month (ppm) in AALS score (A) and 
ALSFRSr (B) over 9 months (36 weeks) in non-A4V patients. Horizontal line represents 
change of controls in cited studies. 
 
Figure 5. Rate of change expressed as points per month (ppm) in AALS score (A) and 
ALSFRSr (B) over 9 months (36 weeks) in 3 A4V /A4T patients.  
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Tables 
 
Number Mutation Gender Age Sx  
Onset 
Site of Onset AALS  
Entry 
1 A4T Male 50 LE 37 
2 A4V Male 51 LE 37 
3 A4V Female 36 LE 42 
4 A4V Female 49 LE 93 
5 A4V Male 40 LE,B 90 
6 A4V Female 49 LE,L 111 
7 L8Q Female 33 UE 82 
8 H46R Female 38 LE 37 
9 H46R Male 37 LE 72 
10 H80Y# Male 51 UE 109 
11 L84F Female 36 LE 100 
12 L84F Male 32 LE 46 
13 N86K male 53 UE 58 
14 D90A  
(heterozygous) 
Male 55 LE 53 
15 D90A  
(heterozygous) 
Male 48 UE 52 
16 G93A Female 37 LE 57 
17 G93D Female 19 LE,R 115 
18 A95T Female 45 LE,L 61 
19 E100G Male 57 LE 79 
20 D109Y Female 59 LE,L 45 
21 I113T Male 67 LE 50 
22 I113T Female 61 UE 63 
23 L117V  
(homozygous) 
Male 44 LE,L 91 
24 R116G male 54 LE 72 
25 R116G female 48 LE 76 
26 V119F# Male 53 BU 51 
27 G127Gfs*7 Female 21 LE 36 
28 G127Gfs*7 Female 48 UE 34 
29 E133K# male 62 LE 59 
30 G148C Female 61 LE 70 
31 L144F Male 58 LE,R 48 
32 L144F Female 53 LE,L 84 
 
Table 1. List of mutations and clinical features; #Novel mutation. LE=lower 
extremities; UE = upper extremities 
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Table 2. Change from Baseline for all measures studied 
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Table 3 
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Table 3. (A) Baseline comparison between drop outs and completers. (B) Multiple 
imputation analysis 
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Figure 1: Baseline values of CSF SOD1 protein content according to mutation in each subject with two 
lumbar punctures.  
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Figure 2. Dose dependent change in CSF SOD1 content in patients with ALS at (A) visit 6 (18 weeks) and 
(B) visit 9 (36 weeks)  
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Figure 3. Percent change from baseline in CSF SOD1 content at 18 weeks of treatment according to 
mutation.  
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Figure 4. Rate of change expressed as points per month (ppm) in AALS score (A) and ALSFRSr (B) over 9 
months (36 weeks) in non-A4V patients. Horizontal line represents change of controls in cited studies.  
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Figure 5. Rate of change expressed as points per month (ppm) in AALS score (A) and ALSFRSr (B) over 9 
months (36 weeks) in 3 A4V /A4T patients.  
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